Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.

Additional reported applications (for the relevant formats) include: immunofluorescence⁴, blocking^6,7,8,9, and immunohistochemistry of acetone-fixed frozen sections^{4, 11}. The LEAF? purified antibody (Endotoxin <0.1 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. No. 124303). For highly sensitive assays, we recommend Ultra-LEAF? purified antibody (Cat. No. 124318) with a lower endotoxin limit than standard LEAF? purified antibodies (Endotoxin <0.01 EU/?g).

1. Maier H, et al. 2007. J. Immunol. 178:2714.
2. Meng Q, et al. 2006. Invest. Ophthalmol. Vis. Sci. 47:4444. PubMed
3. Scarlett UK, et al. 2012. J Exp Med. 209:495. PubMed
4. Grabie N, et al. 2007. Circulation 116:2062. (IF, IHC)
5. Paterson AM, et al. 2011. J. Immunol. 187:1097.
6. Channappanavar R, et al. 2012. PLoS One 7:e39757. (Block)
7. Schreiber HA, et al. 2010. PLoS One 5:e11453. (Block) PubMed
8. Muthumani K, et al. 2011. J. Immunol. 187:2932. (Block) PubMed
9. Cripps JG, et al. 2010. Hepatology 52:1350. (Block) PubMed
10. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
11. Riella LV, et al. 2011. Am. J. Transplant 11:832-40. (IHC)
12. Lei GS, et al. 2015. Infect Immun. 83:572. PubMed

1. Ngiow S, et al. 2016. Cancer Res . 76: 6266 - 6277. PubMed
2. Saha D et al. 2017. Cancer cell. 32(2):253-267 . PubMed
3. Chan LC, et al. 2019. J Clin Invest. 129:3324. PubMed
4. Yonemitsu K, et al. 2022. Sci Rep. 12:12007. PubMed
5. Tatsuguchi T, et al. 2022. Int Immunol. 34:277. PubMed
6. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
7. Pierini S, et al. 2021. J Immunother Cancer. 9:. PubMed
8. Park S, et al. 2021. Front Immunol. 11:620166. PubMed
9. Kiritsy MC, et al. 2021. Elife. 10:. PubMed
10. Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed
11. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
12. Kim TJ, et al. 2019. Nat Commun. 10:3258. PubMed
13. Lin R, et al. 2020. Sci Rep. 10:14397. PubMed
14. Zhang C, et al. 2022. J Extracell Vesicles. 11:e12209. PubMed
15. Ren J, et al. 2021. Theranostics. 11:304. PubMed
16. Chen L, et al. 2020. Cancer Immunol Res. 0.457638889. PubMed
17. Fu Y, et al. 2020. Sci Rep. 10:9027. PubMed
18. Choi H et al. 2019. Cell Rep. 27(3):806-819 . PubMed
19. Bommireddy R, et al. 2020. Vaccines (Basel). 8:. PubMed
20. Findlay EG, et al. 2019. Oncoimmunology. 8:1608106. PubMed
21. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
22. Zhang C, et al. 2020. Cell Metabolism. 31(1):148-161.e5.. PubMed
23. Zhou KX, et al. 2021. J Immunol Res. 2021:6694392. PubMed
24. Tu J, et al. 2022. Theranostics. 12:747. PubMed
25. Davidson S, et al. 2020. Cell Reports. 31(7):107628. PubMed
26. Pein M, et al. 2020. Nat Commun. 11:1494. PubMed
27. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
28. Zhang P, et al. 2022. BMC Med. 20:435. PubMed
29. Guo L, et al. 2021. Front Immunol. 12:785457. PubMed
30. Lovisa S, et al. 2020. Sci Signal. 13:00. PubMed
31. Zhou L, et al. 2020. Clin Cancer Res. 26:290. PubMed
32. Hu Q, et al. 2018. Nat Biomed Eng. 0.660416667. PubMed
33. Kennedy EM, et al. 2022. Nat Commun. 13:5907. PubMed
34. Pradhan K, et al. 2021. Front Immunol. 12:778830. PubMed
35. Poon E, et al. 2017. J Immunother Cancer. 10.1186/s40425-017-0268-8. PubMed
36. Holokai L, et al. 2020. Cancers (Basel). 12:00. PubMed
37. Rashid MH, et al. 2021. Oncol Rep. 45:1171. PubMed
38. Huang L, et al. 2021. Breast Cancer Res Treat. Online ahead of print. PubMed
39. Koikawa K, et al. 2021. Cell. 184(18):4753-4771.e27. PubMed
40. Vardhana SA, et al. 2020. Nat Immunol. 1.584722222. PubMed
41. Ying Zhang et al. 2017. Cancer cell. 32(3):377-391 . PubMed
42. Zhang X, et al. 2021. Mol Cancer Res. 19:1076. PubMed
43. Almishri W, et al. 2015. J Hepatol. 63: 943-951. PubMed
44. Fukumoto T, et al. 2019. Cancer Res. 79:5482. PubMed
45. Yuan M, et al. 2022. Oxid Med Cell Longev. 2022:5479491. PubMed
46. Shen ZY, et al. 2021. Front Immunol. 12:589200. PubMed
47. Williams JB, et al. 2020. Nat Commun. 0.876388889. PubMed
48. Franklin DA, et al. 2020. JCI Insight. 5:. PubMed
49. Baldwin LA, et al. 2022. Nat Commun. 13:6539. PubMed
50. Barbet G, et al. 2018. Immunity. 48:584. PubMed
51. Iwata TN, et al. 2018. Mol Cancer Ther. 17:1494. PubMed
52. Yi M, et al. 2022. J Hematol Oncol. 15:142. PubMed
53. Li Q, et al. 2022. Front Oncol. 12:841977. PubMed
54. Lindhorst A, et al. 2021. Cell Death Dis. 12:579. PubMed
55. Vogel A, et al. 2022. Cell Rep. 38:110420. PubMed
56. Wang R, et al. 2022. J Immunother Cancer. 10:. PubMed
57. Kataru RP, et al. 2019. Cancer Immunol Res. 7:1345. PubMed
58. Renner K, et al. 2020. Cell Reports. 29(1):135-150.e9.. PubMed
59. Zheng C, et al. 2022. Acta Pharm Sin B. 12:3726. PubMed
60. Shen H, et al. 2022. Nat Commun. 13:5013. PubMed
61. Lin J, et al. 2021. Cancer Immunol Res. 9:1413. PubMed
62. Liu YS, et al. 2021. Cancers (Basel). 13:. PubMed
63. Luna-Yolba R, et al. 2021. Cancers (Basel). 13: . PubMed
64. Freed-Pastor WA, et al. 2021. Cancer Cell. :. PubMed
65. Wang C, et al. 2018. Sci Transl Med. 10. PubMed
66. Shaashua L, et al. 2022. Nat Commun. 13:6513. PubMed
67. RL M, et al. 2015. Proc Natl Acad Sci U S A. 112:6506-6514. PubMed
68. Lerbs T, et al. 2020. JCI Insight. 5:00. PubMed
69. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
70. Song X, et al. 2022. Transl Oncol. 15:101306. PubMed
71. Luo N, et al. 2018. Nat Commun. 0.547222222. PubMed

T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes

1. Sharpe A, et al. 2007. Nat. Immunol. 8:239.
2. Dong H, et al. 1999. Nat. Med. 5:1365.
3. Freeman G, et al. 2000. J. Exp. Med. 192:1027.